R-GCD regimen in elderly patients with relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma: a retrospective single-center analysis

Int J Hematol. 2022 Feb;115(2):296-297. doi: 10.1007/s12185-021-03265-w. Epub 2021 Nov 23.

Authors

Toshiya Hino¹, Akira Honda¹, Arika Shimura¹, Yosuke Masamoto¹, Mineo Kurokawa^{2

3}

Affiliations

¹ Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, Japan.
² Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, Japan. kurokawa-tky@umin.ac.jp.
³ Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, Japan. kurokawa-tky@umin.ac.jp.

PMID: 34813046
DOI: 10.1007/s12185-021-03265-w

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Cisplatin / administration & dosage
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Dexamethasone / administration & dosage
Disease-Free Survival
Female
Gemcitabine
Humans
Lymphoma, B-Cell / drug therapy*
Lymphoma, B-Cell / mortality*
Male
Retrospective Studies
Survival Rate

Substances

Deoxycytidine
Dexamethasone
Cisplatin
Gemcitabine